Immunology in Colorado

Immunologic Research

, Volume 55, Issue 1, pp 249-260

Humoral immunity in the Friend retrovirus infection model

  • Kalani HalemanoAffiliated withDivision of Infectious Diseases, University of Colorado DenverDepartment of Microbiology, University of Colorado Denver
  • , Michael S. HarperAffiliated withDivision of Infectious Diseases, University of Colorado DenverIntegrated Department of Immunology, University of Colorado Denver
  • , Kejun GuoAffiliated withDivision of Infectious Diseases, University of Colorado Denver
  • , Sam X. LiAffiliated withDivision of Infectious Diseases, University of Colorado DenverDepartment of Microbiology, University of Colorado Denver
  • , Karl J. HeilmanAffiliated withDivision of Infectious Diseases, University of Colorado Denver
  • , Bradley S. BarrettAffiliated withDivision of Infectious Diseases, University of Colorado Denver
  • , Mario L. SantiagoAffiliated withDivision of Infectious Diseases, University of Colorado DenverDepartment of Microbiology, University of Colorado DenverIntegrated Department of Immunology, University of Colorado Denver Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Major conceptual roadblocks impede the development of an HIV-1 vaccine that can stimulate a potent neutralizing antibody response. Animal models that support HIV-1 replication and allow for host genetic manipulation would be an ideal platform for testing various immunological hypotheses, but progress on this research front has been slow and disappointing. In contrast, many valuable concepts emerged from more than 50 years of studying the Friend retrovirus model. This was recently exemplified by the identification of an innate restriction gene, Apobec3, that could promote the retrovirus-specific neutralizing antibody response. Here we review both classical and recent data on humoral immunity against Friend retrovirus infection, and highlight the potential of this model for unraveling novel aspects of the retrovirus-specific antibody response that may guide HIV-1 vaccine development efforts.

Keywords

Friend retrovirus HIV APOBEC3 Rfv3 Neutralizing antibodies Vaccines